The company will work with university researchers to evaluate its predictive immune modeling technology in personalizing the use of immune checkpoint inhibitors.
The company has pivoted to serve the research market but still hopes to spearhead translation of immunotherapy biomarkers following CLIA validation of its approach.
Cofactor's kit will be used to characterize the immune responses generated in reaction to treatment with an investigational personalized cancer vaccine.
The platform will be designed to gather all necessary data from a single RNA extraction, eliminating the need for flow cytometry, genomic sequencing, and expression profiling.
The companies will combine Cofactor's RNA-seq know-how with SII's big data analytics offerings to provide services for pharmaceutical research customers.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.
